South Korea Finalizes 2026-2027 Influenza Vaccine Procurement Contract
The Korea Disease Control and Prevention Agency (KDCA) has confirmed the procurement of 12.33 million influenza vaccine doses for the 2026-2027 season, according to an official announcement. This decision follows a competitive bidding process and incorporates data from the previous season’s vaccination rates and local government demand surveys conducted in March and April 2026.
What is the scale of the 2026-2027 influenza vaccine procurement?
The KDCA secured 12.33 million doses through a procurement contract, reflecting adjustments based on historical vaccination data and projected needs. The agency stated that the volume was determined by analyzing the 2025-2026 season’s actual usage, anticipated vaccination rates, and regional demand assessments. This figure aligns with the government’s goal to ensure widespread access to influenza vaccines amid growing public health concerns.
How were the vaccine manufacturers selected?
Six companies were chosen through a competitive bidding process under the Ministry of Public Administration and Safety’s procurement guidelines. SK Biopharmaceuticals, LG Chem (formerly known as LG Life Sciences), and other firms were selected based on their ability to provide the lowest prices, with prioritization given to suppliers offering higher volumes at the same cost. The list of participants includes SK Biopharmaceuticals, LG Chem, and three other unnamed manufacturers, according to the KDCA.
What measures are in place to ensure vaccine safety during distribution?
KDCA Director Im Seung-gwan emphasized that all selected manufacturers will undergo rigorous inspections of storage facilities and transportation equipment before vaccine distribution begins. “We are conducting thorough on-site checks to ensure that vaccines are stored and transported under safe conditions, guaranteeing the effectiveness of the vaccination program,” Im stated. The agency also reiterated its commitment to monitoring cold-chain logistics throughout the supply chain.
Why is this procurement significant for public health?
Influenza vaccination campaigns are critical for reducing seasonal outbreaks, particularly in regions with high population density like South Korea. The 2026-2027 procurement follows a 2025-2026 season marked by increased cases of respiratory illnesses, prompting officials to prioritize vaccine availability. The KDCA’s approach reflects a strategy to mitigate future surges by maintaining a stable supply of vaccines, supported by partnerships with multiple manufacturers.
What are the next steps for the vaccination program?
The KDCA plans to begin distributing vaccines in late September 2026, with priority given to high-risk groups, including the elderly and individuals with chronic health conditions. The agency will also launch public awareness campaigns to encourage participation, citing a 2025-2026 vaccination rate of 42% among eligible citizens as a benchmark for improvement.
Korea Disease Control and Prevention Agency
Worth a look